<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="561">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153850</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-COV-2021-01</org_study_id>
    <nct_id>NCT05153850</nct_id>
  </id_info>
  <brief_title>Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2</brief_title>
  <official_title>Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2 in Patients With Inflammatory Bowel Disease Under Inmunosuppressor Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational single-center study in which the impact of anti-TNF biological&#xD;
      treatment on the humoral response after complete vaccination against SARS-COV2 in patients&#xD;
      with inflammatory bowel disease is analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective observational single-center study in which the impact of anti-TNF biological&#xD;
      treatment on the humoral response after complete vaccination against SARS-COV2 in patients&#xD;
      with inflammatory bowel disease is analyzed.&#xD;
&#xD;
      The first objective is to compare the seroconversion rate after full vaccination against&#xD;
      SARS-COV2 in patients with IBD treated with anti-TNF drugs versus patients treated with&#xD;
      Ustekinumab / Vedolizumab and patients without immunosuppressive treatment.&#xD;
&#xD;
      The Patients included in the study belong to the health area of the Virgen Macarena&#xD;
      University Hospital who meet the following inclusion criteria and none for exclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with peripheral blood antibodies against SARS-COV2.</measure>
    <time_frame>Up to 16 weeks.</time_frame>
    <description>Seroconversion rate against SARS-COV2 defined as the presence of antibodies in peripheral blood four months after the complete vaccination schedule against SARS-COV2.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">243</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients diagnosed with inflammatory bowel disease with the complete vaccination regimen.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients included in the study are elderly patients suffering from inflammatory bowel&#xD;
        disease and have completed their vaccination schedule against the SARS-COV-2 virus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be of legal age (&gt; 18 years).&#xD;
&#xD;
          -  Diagnosis of inflammatory bowel disease (Crohn's Disease or Ulcerative Colitis).&#xD;
&#xD;
          -  Complete vaccination schedule (one or two doses depending on previous SARS-Cov2&#xD;
             infection) between one and four months prior to the determination of anti-SARS-Cov2&#xD;
             antibodies.&#xD;
&#xD;
          -  Treatment with biological therapy for at least 6 weeks prior to the time of&#xD;
             vaccination for the group of patients treated with biological drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Last vaccination dose more than four months ago from the determination of antibodies&#xD;
             against SARS-Cov2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Federico Argüelles Arias</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Argüelles Arias</last_name>
    <phone>955 00 80 00</phone>
    <email>farguelles@telefonica.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 04 31 27</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Federico Argüelles Arias</last_name>
      <phone>955 00 80 00</phone>
      <email>farguelles@telefonica.net</email>
    </contact>
    <contact_backup>
      <last_name>Carlos García Pérez</last_name>
      <phone>955 04 31 27</phone>
      <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

